Cell-based therapies: careful safety assessment for minimization of risk

References

• Falkenburg JH, Heslop HE, Barrett AJ. T-cell therapy in allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(Suppl 1):136–41.
   PubMed Web of Science ®Google Scholar
• Fujita Y, Rooney CM, Heslop HE. Adoptive cellular immunotherapy for viral diseases. Bone Marrow Transplant 2008; 41:193–8.
   PubMed Web of Science ®Google Scholar
• Comoli P, Locatelli F, Ginevri F, Maccario R. Cellular immunotherapy for viral infections in solid organ transplant recipients. Curr Opin Organ Transplant 2002;7:314–19.
   Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008;8:299–308.
   PubMed Web of Science ®Google Scholar
• Riley JL, June CH, Blazar BR. Human T regulatory cells as therapeutic agents: take a billion or so of these and call me in the morning. Immunity 2009;30:656–65.
   PubMed Web of Science ®Google Scholar
• Merlo A, Turrini R, Dolcetti R, . The interplay between EBV and the immune system: a rationale for adoptive cell therapy of EBV-related disorders. Haematologica 2010; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, . Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive meloablative chemoradiation preparative regimens. J Clin Oncol 2008; 26:5233–9.
   PubMed Web of Science ®Google Scholar
• Heslop HE, Slobod KS, Pule MA, Hale GA, Rousseau A, Smith CA, . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010;115:925–35.
   PubMed Web of Science ®Google Scholar
• Haque T, Wilkie GM, Jones MM, Higgins CD, Urquhart G, Wingate P, . Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood 2007; 110:1123–31.
   PubMed Web of Science ®Google Scholar
• Comoli P, Locatelli F. T-cell therapy for the treatment of Epstein Barr virus-associated malignancies. Immunother Insights 2009;1:13–4.
   PubMedGoogle Scholar
• Burger SR. Current regulatory issues in cell and tissue therapy. Cytotherapy 2003;5(4):289–98.
   PubMed Web of Science ®Google Scholar
• Alessandrino P, Bernasconi P, Caldera D, Colombo A, Bonfichi M, Malcovati L, . Adverse events occurring during bone marrow or peripheral blood progenitor cell infusion: analysis of 26 cases. Bone Marrow Transplant 1999 Mar;23(6):533–7.
   PubMed Web of Science ®Google Scholar
• Cruz CR, Hanley P, Liu H, Torrano V, Lin Y, Arce JA, . Adverse events following infusion of T cells for adoptive immunotherapy. Cytotherapy 2010;12:742–8.
   Web of Science ®Google Scholar
• Rooney CM, Smith CA, Ng CYC, Loftin SK, Sixbey JW, Gan Y, . Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998,92:1549–55.
   PubMed Web of Science ®Google Scholar
• Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18:843–51.
   PubMed Web of Science ®Google Scholar
• Brentjens RJ, Riviere I, Hollyman D, Taylor C, Nikhamin Y, Stefansky J, Lee J, . Unexpected toxicity of cyclophosphamide followed by adoptively transferred CD19-targeted T cells in a patient with bulky CLL. Molecular Therapy 2009;17 (Suppl 1):S157.
   Google Scholar
• Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, . Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28.
   PubMed Web of Science ®Google Scholar
• Torsvik A, Røsland GV, Svendsen A, Molven A, Immervoll H, McCormack E, . Spontaneous malignant transformation of human mesenchymal stem cells reflects cross-contamination: putting the research field on track - letter. Cancer Res. 2010 Jul 14. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Bernardo ME, Zaffaroni N, Novara F, Cometa AM, Avanzini MA, Moretta A, . Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007;67:9142–9.
   PubMed Web of Science ®Google Scholar